guid ind file trial start
messag report earn in-lin expect
compani continu execut across pipelin focus develop next-gen
select tki remain on-track near-term data readout near-
term newsflow includ data updat reportrectinib
ret esmo see well ind submiss develop
candid select inhibitor later year data updat
includ phase result repotrectinib
interim analyst updat estim reflect financi result
maintain buy rate
on-track toward develop potenti best-in-class tki trk
phase updat esmo see esmo planner note consist mostli
efficaci popul report previous addit month follow-
small number addl evalu tki-pretr patient data may set
stage interim readout registr cohort
lung ntrk solid cancer call announc fda recent
accept compani recommend phase ii dose regimen consist
mg daili dose first day follow option up-titr mg twice
daili base patient toler
preclin poster compar ret inhibitor
surrog molecul esmo see esmo
planner note competit front inhibitor entrectinib
upcom pdufa date phase program
read initi clinic data see phase initi note
phase trial recent initi see ind file guid
updat estim reflect result end quarter
cash invest updat estim maintain buy rate pt
page analyst certif import disclosur
valu per share use dcf analysi use wacc
consist clinical-stag biotech compani cover proof-of-concept data well
termin growth rate risk includ regulatori commerci setback potenti emerg
new competitor lower product sale expect dilut financ beyond
page analyst certif import disclosur
total cost expens
interest incom net
loss extinguish debt
incom tax
guggenheim secur llc sec file
page analyst certif import disclosur
